Rufinamide-Loaded Chitosan Nanoparticles in Xyloglucan-Based Thermoresponsive In Situ Gel for Direct Nose to Brain Delivery

• Hauptverfasser: Avantika Dalvi (Verfasst von), Punna Rao Ravi (Verfasst von), Chandra Teja Uppuluri (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2021-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

In 2004, the US FDA approved Rufinamide, an anti-epileptic drug under the brand name Banzel®. In 2015, Banzel® received approval for its use in pediatric patients (ages 1-4 years). Rufinamide shows low oral bioavailability due to a low dissolution rate resulting in less of the drug reaching the brai...